Iron depletion before HCV antiviral therapy: A pilot, randomized, controlled trial

Journal of Clinical Apheresis

Volumn 24, Issue 5, 2009, Pages 190-196

  Gentile, Ivan ^a   Viola, Chiara ^a   Paesano, Luigi ^b   D'Onofrio, Marcello ^b   D'Agostino, Elio ^a   Cerini, Raimondo ^a   Borrelli, Francesco ^a   Piazza, Marcello ^a   Borgia, Guglielmo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b San Giovanni Bosco Hospital   (Italy)

Author keywords

Blood letting; Ferritin; Iron; Pegylated interferon; Phlebotomy; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; FERRITIN; HEMOGLOBIN; IRON; PEGINTERFERON ALPHA2B; RIBAVIRIN; TRANSFERRIN; VIRUS RNA;

ADULT; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERTHYROIDISM; MALE; NEUTROPENIA; PHLEBOTOMY; PILOT STUDY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SYNCOPE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VOMITING;

ANTIVIRAL AGENTS; FEMALE; FERRITINS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; IRON; MALE; MIDDLE AGED; PHLEBOTOMY; PILOT PROJECTS; POLYETHYLENE GLYCOLS; RIBAVIRIN; TRANSFERRIN;

EID: 70449601851     PISSN: 07332459     EISSN: 10981101     Source Type: Journal    
DOI: 10.1002/jca.20210     Document Type: Article

References (38)

1. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002;36 (Suppl 1):S21-S29.
2. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002;36 (Suppl 1):S35-S46.
3. El-Serag HB. Hepatocellular carcinoma and hepatitis C in United States. Hepatology 2002;36 (Suppl 1):S74-S83.
4. Di Bisceglie AM, Axiotis CA, Hoofnagle JH, Bacon BR. Measurements of iron status in patients with chronic hepatitis. Gastroenterology 1992;102:2108-2113.
5. Fischer R, Piga A, Harmatz P, Nielsen P. Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry. Ann NY Acad Sci 2005;1054:350-357.
6. Bonkovsky HL, Banner BF, Rothman AL. Iron and chronic viral hepatitis. Hepatology 1997;25:759-768.
7. Sebastiani G, Vario A, Ferrari A, Pistis R, Noventa F, Alberti A. Hepatic iron, liver steatosis and viral genotypes in patients with chronic hepatitis C. J Viral Hepat 2006;13:199-205.
8. Beinker NK, Voigt MD, Arendse M, Smit J, Stander IA, Kirsch RE. Threshold effect of liver iron content on hepatic inflammation and fibrosis in hepatitis B and C. J Hepatol 1996;25:633-638.
9. Sartori M, Andorno S, La Terra G, Boldorini R, Leone F, Pittau S, Zecchina G, Aglietta M, Saglio G. Evaluation of iron status in patients with chronic hepatitis C. Ital J Gastroenterol Hepatol 1998;30:396-401.
10. Casaril M, Stanzial AM, Tognella P, Pantalena M, Capra F, Colombari R, Corrocher R. Role of iron load on fibrogenesis in chronic hepatitis C. Hepatogastroenterology 2000;47:220-225.
11. Fujita N, Sugimoto R, Urawa N, Araki J, Mifuji R, Yamamoto M, Horiike S, Tanaka H, Iwasa M, Kobayashi Y, Adachi Y, Kaito M. Hepatic iron accumulation is associated with disease progression and resistance to interferon/ribavirin combination therapy in chronic hepatitis C. J Gastroenterol Hepatol 2007;22:1886-1893.
12. Van Thiel DH, Friedlander L, Fagiuoli S, Wright HI, Irish W, Gavaler JS. Response to interferon a therapy is influenced by the iron content of the liver. J Hepatol 1994;20:410-415.
13. Olynyk JK, Reddy KR, Di Bisceglie AM, Jeffers LJ, Parker TI, Radick JL, Schiff ER, Bacon BR. Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. Gastroenterology 1995;108:1104-1109.
14. Fong TL, Han SH, Tsai NC, Morgan TR, Mizokami M, Qian D, Phan C, Goad K, Redeker AG. A pilot randomized, controlled trial of the effect of iron depletion on long-term response to alpha-interferon in patients with chronic hepatitis C. J Hepatol 1998;28:369-374.
15. Fontana RJ, Israel J, Leclair P, Banner BF, Tortorelli K, Grace N, Levine RA, Fiarman G, Thiim M, Tavill AS, Bonkovsky HL. Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial. Hepatology 2000;31:730-736.
16. Fargion S, Fracanzani AL, Rossini A, Borzio M, Riggio O, Belloni G, Bissoli F, Ceriani R, Ballarè M, Massari M, Trischitta C, Fiore P, Orlandi A, Morini L, Mattioli M, Oldani S, Cesana B, Fiorelli G. Iron reduction and sustained response to interferon a therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study. Am J Gastroenterol 2002;97:1204-1210.
17. Van Thiel DH, Van Thiel DH, Friedlander L, Molloy PJ, Kania RJ, Fagiuoli S, Wright HI, Gasbarrini A, Caraceni P. Retreatment of hepatitis C interferon nonresponders with larger doses of interferon with and without phlebotomy. Hepatogastrenterology 1996;43:1557-1561.
18. Di Bisceglie AM, Bonkovsky HL, Chopra S, Flamm S, Reddy RK, Grace N, Killenberg P, Hunt C, Tamburro C, Tavill AS, Ferguson R, Krawitt E, Banner B, Bacon BR. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial. Hepatology 2000;32:135-138.
19. Herrera JL. Iron depletion is not effective in inducing a virologic response in patients with chronic hepatitis C who failed to respond to interferon therapy. Am J Gastroenterol 1999;94:3571-3575.
20. Tsai NC, Zuckerman E, Han SH, Goad K, Redeker AG, Fong TL. Effect of iron depletion on long-term response to interferon-alpha in patients with chronic hepatitis C who previously did not respond to interferon therapy. Am J Gastroenterol 1997;92:1831-1834.
21. Distante S, Bjøro K, Hellum KB, Myrvang B, Berg JP, Skaug K, Raknerud N, Bell H. Raised serum ferritin predicts nonresponse to interferon and ribavirin treatment in patients with chronic hepatitis C infection. Liver 2002;22:269-275.
22. Shedlofsky SI. Does iron reduction improve sustained viral responses to interferon monotherapy in hepatitis C patients? Maybe, but is this the right question? Am J Gastroenterol 2002;97:1093-1096.
23. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, Macsween RN, Phillips MJ, Portmann BG, Poulsen H, Scheuer PJ, Schmid M, Thaler H. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-699.
24. Lok AS, Ghany MG, Goodman ZD, Wright EC, Everson GT, Sterling RK, Everhart JE, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morgan TR, Dienstag JL, Morishima C. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology 2005;42:282-292.
25. Ghany MG, Strader DB, Thomas DL, Seeff LB. American association for the study of liver diseases. diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-1374.
26. Pietrangelo A. Hemochromatosis: an endocrine liver disease. Hepatology 2007;46:1291-1301.
27. Nishina S, Hino K, Korenaga M, Vecchi C, Pietrangelo A, Mizukami Y, Furutani T, Sakai A, Okuda M, Hidaka I, Okita K, Sakaida I. Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. Gastroenterology 2008;134:226-238.
28. Valenti L, Pulixi EA, Arosio P, Cremonesi L, Biasiotto G, Dongiovanni P, Maggioni M, Fargion S, Fracanzani AL. Relative contribution of iron genes, dysmetabolism and hepatitis C virus (HCV) in the pathogenesis of altered iron regulation in HCV chronic hepatitis. Haematologica 2007;92:1037-1042.
29. Erhardt A, Maschner-Olberg A, Mellenthin C, Kappert G, Adams O, Donner A, Willers R, Niederau C, Häussinger D. HFE mutations and chronic hepatitis C: H63D and C282Y heterozygosity are independent risk factors for liver fibrosis and cirrhosis. J Hepatol 2003;38:335-342.
30. Lebray P, Zylberberg H, Hue S, Poulet B, Carnot F, Martin S, Chretien Y, Pol S, Caillat-Zuckman S, Bréchot C, Nalpas B. Influence of HFE gene polymorphism on the progression and treatment of chronic hepatitis C. J Viral Hepat 2004;11:175-182.
31. Coelho-Borges S, Cheinquer H, Cheinquer N, Krug L. Ashton-Prolla P HFE gene mutations prevent sustained virological response to interferon plus ribavirin in chronic hepatitis C patients with serum markers of iron overload. Am J Gastroenterol 2002;97:1570-1572.
32. Bonkovsky HL, Naishadham D, Lambrecht RW, Chung RT, Hoefs JC, Nash SR, Rogers TE, Banner BF, Sterling RK, Donovan JA, Fontana RJ, Di Bisceglie AM, Ghany MG, Morishima C. HALT-C Trial Group. Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology 2006;131:1440-1451.
33. Fabris C, Toniutto P, Scott CA, Falleti E, Avellini C, Del Forno M, Mattiuzzo M, Branca B, Pirisi M. Serum iron indices as a measure of iron deposits in chronic hepatitis C. Clin Chim Acta 2001;304:49-55.
34. Bassett ML. Iron and hepatitis C: beginning to make sense. J Gastroenterol Hepatol 2007;22:1703-1704.
35. Hayashi H, Takikawa T, Nishimura N, Yano M, Isomura T, Sakamoto N. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am J Gastroenterol 1994;89:986-988.
36. Piperno A, Sampietro M, D'alba R, Roffi L, Fargion S, Parma S, Nicoli C, Corbetta N, Pozzi M, Arosio V, Boari G, Fiorelli G. Iron stores, response to alpha-interferon therapy, and effects of iron depletion in chronic hepatitis C. Liver 1996;16:248-254.
37. Homoncik M, Jilma-Stohlawetz P, Schmid M, Ferlitsch A, Peck-Radosavljevic M. Erythropoietin increases platelet reactivity and platelet counts in patients with alcoholic liver cirrhosis: a randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2004;20:437-443.
38. Conrad ME, Umbreit JN. Pathways of iron absorption. Blood Cells Mol Dis 2002;29:336-355.